阿斯利康抢跑,超20亿元授权,还能帮来凯医药赢得多大商业机会?

钛媒体APP
Nov 13, 2025

文 | 医药研究社对于来凯医药来说,“临床产品商业化”这一重要时刻是越来越近了。11月12日,该公司发布公告称,根据许可协议的条款与条件,齐鲁制药获授独家许可,于中国地区(包括中国内地、香港特别行政区、澳门特别行政区及中国台湾地区)进行LAE002 (afuresertib)的研究、开发及商业化。另外,作为回报,直至首个适应症在中国获得新药申请批准,来凯医药有权获得最高总计人民币5.3亿元不可退还...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10